

2026 Regular Session

HOUSE CONCURRENT RESOLUTION NO. 72

BY REPRESENTATIVES BEAULLIEU, ADAMS, AMEDEE, BAGLEY, BAMBURG, BAYHAM, BERAULT, BILLINGS, BOUDREAUX, BOURRIAQUE, BOYD, BOYER, BRASS, BROUSSARD, BRYANT, BUTLER, CARLSON, CARRIER, CARVER, CHASSION, CHENEVERT, COATES, COX, DESHOTEL, DEVILLIER, DEWITT, DICKERSON, DOMANGUE, ECHOLS, EDMONSTON, EGAN, FARNUM, FIRMENT, FISHER, FREEMAN, FREIBERG, GLORIOSO, HEBERT, CHANCE HENRY, DANA HENRY, HILFERTY, HORTON, ILLG, JACKSON, MIKE JOHNSON, TRAVIS JOHNSON, JORDAN, KERNER, KNOX, LACOMBE, LAFLEUR, JACOB LANDRY, TERRY LANDRY, LARVADAIN, LYONS, MARCELLE, MARTINEZ, MCFARLAND, MCMAHEN, MCMAKIN, MELERINE, MILLER, MOORE, MURRAY, MUSCARELLO, NEWELL, ORGERON, OWEN, PHELPS, RISER, SAWYER, SCHAMERHORN, SCHLEGEL, SPELL, ST. BLANC, STAGNI, TAYLOR, VENTRELLA, VILLIO, WALTERS, WILDER, WILEY, WRIGHT, WYBLE, AND YOUNG

A CONCURRENT RESOLUTION

To memorialize the United States Congress to expedite and prioritize research, clinical trials, and treatment development related to Acute Myeloid Leukemia and to designate such efforts as the "Jonas A. Feeley Act".

WHEREAS, Acute Myeloid Leukemia is a rare and aggressive blood cancer characterized by the rapid proliferation of abnormal myeloid cells resulting in life-threatening complications and a high mortality rate; and

WHEREAS, Acute Myeloid Leukemia often progresses within days or weeks of diagnosis, leaving patients and families with extremely limited windows for treatment and intervention; and

WHEREAS, despite advancements in oncology and hematology, the overall five-year survival rate for Acute Myeloid Leukemia remains approximately thirty percent, underscoring the urgent need for expanded research, improved therapies, and accelerated clinical trials; and

WHEREAS, Jonas A. Feeley was unexpectedly diagnosed with Acute Myeloid Leukemia on December 17, 2025, and passed away on December 18, 2025, demonstrating the devastating speed, severity, and unpredictability of this disease; and

WHEREAS, Jonas A. Feeley was a devoted husband, family member, and friend whose life, character, and service left a lasting impact on his loved ones and community; and

WHEREAS, increased federal investment in early detection, biomedical research, and innovative treatment options for Acute Myeloid Leukemia has the potential to save lives, improve outcomes, and reduce the emotional and financial burden on families nationwide; and

WHEREAS, veterans and other populations with environmental and occupational exposures may face elevated risks for hematologic malignancies, including Acute Myeloid Leukemia; and

WHEREAS, state legislatures have a long-standing role in urging federal action on matters of national health importance and in advocating for policies that advance medical research and public welfare.

THEREFORE, BE IT RESOLVED that the Legislature of Louisiana does hereby memorialize the Congress of the United States, the National Institutes of Health, the National Cancer Institute, and the Department of Health and Human Services to expedite and prioritize research, clinical trials, and treatment development related to Acute Myeloid Leukemia.

BE IT FURTHER RESOLVED that such accelerated federal efforts be collectively designated and recognized as the "Jonas A. Feeley Act", in honor of his life, and in recognition of all individuals and families affected by Acute Myeloid Leukemia.

BE IT FURTHER RESOLVED that a copy of this Resolution be transmitted to the presiding officers of the Senate and the House of Representatives of the Congress of the United States of America, the Louisiana congressional delegation, the secretary of the United States Department of Health and Human Services, and the directors of the National Institutes of Health and the National Cancer Institute.

---

SPEAKER OF THE HOUSE OF REPRESENTATIVES

---

PRESIDENT OF THE SENATE